Do's and Don'ts for DOAC Use in Special Populations
Numerous randomized controlled trials have demonstrated direct oral anticoagulant (DOAC) noninferiority/superiority to warfarin in thrombosis treatment and prevention, as well as lowered rates of bleeding. However, a gap in evidence exists for the use of DOACs in special patient populations, and fewer clear recommendations for optimal DOAC dosing strategies exist. This CE activity will educate pharmacists on the most recent evidence regarding the use of DOACs in special patient populations, specifically patients of extreme body weight, those with end-stage renal disease, and the elderly over 75 years of age.
Learning Objectives
Upon completion of this activity, the participant will be able to:
- Explain the current standards of care for using direct oral anticoagulants (DOACs) in patients with venous thromboembolism or non-valvular atrial fibrillation according to guideline recommendations.
- Analyze and evaluate recent evidence for the use of DOACs in special patient populations, including patients of either extremes in body weight, those with end-stage renal disease, or elderly patients.
- Develop an appropriate DOAC-specific dosing and monitoring plan for patients of special populations.
- Assess the pharmacist’s role in formulating anticoagulation regimens for patients of special populations.
Presenter
Samantha Schermerhorn, PharmD, is a PGY1 Pharmacy Resident at Baystate Medical Center in Springfield, MA. Samantha earned her Doctor of Pharmacy degree in May 2021 from Wegmans School of Pharmacy, St. John Fisher College in Rochester, NY. Samantha’s interest areas include ambulatory care, cardiovascular disease state management, and academia.
Registration Fee: This module is provided free of charge to all.
Release Date: June 15, 2022
Expiration Date: June 15, 2023
ACPE UAN: 0026-0000-22-134-H01-P | Application
ACPE Topic Designator: Disease State Management/Drug Therapy
Contact Hours: 1.0 (0.1 CEU)
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Massachusetts College of Pharmacy and Health Sciences designates this activity for a total of 1.0 contact hour (0.1 CEUs).
In order to receive credit, the participant must view the entire presentation and complete the pre and post-tests, and evaluation form. Upon completion, participant credit will be reported to CPE Monitor. Transcripts may be printed from CPE Monitor.
The policy of Massachusetts College of Pharmacy and Health Sciences is ensuring balance, independence, objectivity, and scientific rigor in all of its educational activities. Any individuals involved in planning or content creation for a continuing education activity are required to disclose financial relationships with ineligible companies that have occurred within the last 24 months. The intent of the policy is to identify and mitigate potential conflicts of interest that may affect the activity. All clinical medicine recommendations must be based on evidence accepted within the medical profession.
Samantha Schermerhorn has no relevant financial relationships with ineligible companies to disclose.
Residency Director Frank Szczerba has no relevant financial relationships with ineligible companies to disclose.
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies related to the content of this presentation.
Massachusetts College of Pharmacy and Health Sciences will identify, review, and mitigate all conflicts of interest disclosed prior to delivery of an educational activity to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but provides participants with information that may be of potential importance when they are evaluating content.